CALCA and migraine disorder: Eptinezumab is a recombinant humanized IgG1 antibody that binds to α and β forms of human CGRP ligand. It prevents the activation of CGRP receptors and hence the downstream cascade of physiological events linked to initiation of migraine attacks. Eptinezumab inhibits α‐ and β‐CGRP‐mediated neurogenic inflammation and vasodilation.